{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:55:40Z","timestamp":1793451340788,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T00:00:00Z","timestamp":1172534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2007,11,28]]},"DOI":"10.1007\/s10549-007-9523-x","type":"journal-article","created":{"date-parts":[[2007,3,16]],"date-time":"2007-03-16T12:44:18Z","timestamp":1174049058000},"page":"103-111","source":"Crossref","is-referenced-by-count":530,"title":["Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study"],"prefix":"10.1007","volume":"107","author":[{"given":"Agn\u00e8s","family":"Fournier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Berrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Clavel-Chapelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,27]]},"reference":[{"key":"9523_CR1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(05)70273-4","volume":"6","author":"V Cogliano","year":"2005","unstructured":"Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552\u2013553","journal-title":"Lancet Oncol"},{"key":"9523_CR2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","volume":"68","author":"FZ Stanczyk","year":"2003","unstructured":"Stanczyk FZ (2003) All progestins are not created equal. Steroids 68:879\u2013890","journal-title":"Steroids"},{"key":"9523_CR3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0960-0760(98)00028-4","volume":"65","author":"JR Pasqualini","year":"1998","unstructured":"Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J (1998) Progestins and breast cancer. J Steroid Biochem Mol Biol 65:225\u2013235","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9523_CR4","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/sj.bjc.6602617","volume":"92","author":"SA Lee","year":"2005","unstructured":"Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049\u20132058","journal-title":"Br J Cancer"},{"key":"9523_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jsbmb.2005.08.015","volume":"97","author":"C Campagnoli","year":"2005","unstructured":"Campagnoli C, Abba C, Ambroggio S, Peris C (2005) Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 97:441\u2013450","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9523_CR6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.295.14.1647","volume":"295","author":"ML Stefanick","year":"2006","unstructured":"Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647\u20131657","journal-title":"JAMA"},{"key":"9523_CR7","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047\u20131059","DOI":"10.1016\/S0140-6736(97)08233-0"},{"key":"9523_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6","volume":"81","author":"C Magnusson","year":"1999","unstructured":"Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81:339\u2013344","journal-title":"Int J Cancer"},{"key":"9523_CR9","first-page":"593","volume":"11","author":"PA Newcomb","year":"2002","unstructured":"Newcomb PA, Titus-Ernstoff L, Egan KM et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593\u2013600","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9523_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","volume":"362","author":"V Beral","year":"2003","unstructured":"Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419\u2013427","journal-title":"Lancet"},{"key":"9523_CR11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.20016","volume":"109","author":"C Stahlberg","year":"2004","unstructured":"Stahlberg C, Pedersen AT, Lynge E et al (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721\u2013727","journal-title":"Int J Cancer"},{"key":"9523_CR12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.20389","volume":"112","author":"K Bakken","year":"2004","unstructured":"Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130\u2013134","journal-title":"Int J Cancer"},{"key":"9523_CR13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/sj.bjc.6602472","volume":"92","author":"M Ewertz","year":"2005","unstructured":"Ewertz M, Mellemkjaer L, Poulsen AH et al (2005) Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92:1293\u20131297","journal-title":"Br J Cancer"},{"key":"9523_CR14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/ijc.21481","volume":"118","author":"S Lee","year":"2006","unstructured":"Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the multiethnic cohort. Int J Cancer 118:1285\u20131291","journal-title":"Int J Cancer"},{"key":"9523_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(05)66519-1","volume":"366","author":"M Hickey","year":"2005","unstructured":"Hickey M, Davis SR, Sturdee DW (2005) Treatment of menopausal symptoms: what shall we do now? Lancet 366:409\u2013421","journal-title":"Lancet"},{"key":"9523_CR16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","volume":"114","author":"A Fournier","year":"2005","unstructured":"Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448\u2013454","journal-title":"Int J Cancer"},{"key":"9523_CR17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1079\/PHN2002394","volume":"5","author":"E Riboli","year":"2002","unstructured":"Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113\u20131124","journal-title":"Public Health Nutr"},{"key":"9523_CR18","first-page":"319","volume":"7","author":"NS Weiss","year":"1996","unstructured":"Weiss NS, Rossing MA (1996) Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiology 7:319\u2013322","journal-title":"Epidemiology"},{"key":"9523_CR19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0039-128X(03)00138-7","volume":"68","author":"RJ Santen","year":"2003","unstructured":"Santen RJ (2003) Risk of breast cancer with progestins: critical assessment of current data. Steroids 68:953\u2013964","journal-title":"Steroids"},{"key":"9523_CR20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/cmt.5.3.229.235","volume":"5","author":"B Lignieres de","year":"2002","unstructured":"de Lignieres B (2002) Effects of progestogens on the postmenopausal breast. Climacteric 5:229\u2013235","journal-title":"Climacteric"},{"key":"9523_CR21","first-page":"502","volume":"18","author":"JD Graham","year":"1997","unstructured":"Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502\u2013519","journal-title":"Endocr Rev"},{"key":"9523_CR22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10549-006-9276-y","volume":"101","author":"CE Wood","year":"2007","unstructured":"Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Mark CJ (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101:125\u2013134","journal-title":"Breast Cancer Res Treat"},{"key":"9523_CR23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1008966623901","volume":"11","author":"P Muti","year":"2000","unstructured":"Muti P, Stanulla M, Micheli A et al (2000) Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes Control 11:721\u2013730","journal-title":"Cancer Causes Control"},{"key":"9523_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.maturitas.2004.05.015","volume":"49","author":"CI Li","year":"2004","unstructured":"Li CI (2004) Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas 49:44\u201350","journal-title":"Maturitas"},{"key":"9523_CR25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915\u2013920","journal-title":"Am J Epidemiol"},{"key":"9523_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/95.1.30","volume":"95","author":"GA Greendale","year":"2003","unstructured":"Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95:30\u201337","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9523-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-007-9523-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9523-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:48Z","timestamp":1559233728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-007-9523-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,11,28]]}},"alternative-id":["9523"],"URL":"https:\/\/doi.org\/10.1007\/s10549-007-9523-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,27]]}}}